In a report released on September 20, Mani Foroohar from SVB Securities maintained a Hold rating on Wave Life Sciences (WVE – Research Report). The company’s shares closed yesterday at $3.92.
According to TipRanks, Foroohar is an analyst with an average return of -13.3% and a 42.86% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as Moderna, Alnylam Pharma, and Bluebird Bio.
Currently, the analyst consensus on Wave Life Sciences is a Moderate Buy with an average price target of $8.00.
See Insiders’ Hot Stocks on TipRanks >>
WVE market cap is currently $316M and has a P/E ratio of -1.84.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Wave Life Sciences Ltd. is a biotechnology company, which engages in the development of proprietary synthetic chemistry drug. It focuses on the design, development, and commercialization of nucleic acid-based therapeutics. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.
Read More on WVE:
- Wave Life Sciences Announces Positive Update from Phase 1b/2a SELECT-HD Trial with Initial Results Indicating Allele-Selective Target Engagement with WVE-003 in Huntington’s Disease
- Wave Life Sciences to Host Analyst and Investor Virtual Event, “Towards the Clinic: Spotlight on RNA Editing for AATD,” on September 28, 2022
- Why Is Wave Life Sciences Stock Surging Despite Q2 Miss?
- Wave Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update
